Gene therapy for rare brain diseases: 5-Year safety check begins

NCT ID NCT06614569

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows 7 people who previously received a gene therapy called AXO-AAV-GM2 for Tay-Sachs or Sandhoff disease — rare, fatal genetic disorders that destroy nerve cells. Researchers will track them for up to 5 years to see if the treatment remains safe and whether it helps slow the disease's natural course. The focus is on long-term side effects and changes in development, movement, and thinking skills.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
AXO-AAV-GM2 gene therapy
What this could lead to
If successful, this could show that a single gene therapy treatment can slow or stabilize the devastating progression of Tay-Sachs and Sandhoff diseases over several years.
What could go wrong
This is a very small, early-stage follow-up study with only 7 participants. It cannot prove the therapy works broadly, and there are risks like cancer or immune disorders that need long-term monitoring.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GM2 GANGLIOSIDOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • UMass Chan Medical School

    Worcester, Massachusetts, 01655, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.